This Article Full Text Full Text (PDF) IMPORTANT FDA ADVISORY eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coleman, R. E. Search for Related Content PubMed PubMed Citation Articles by Coleman, R. E.

Bisphosphonates: Clinical Experience

Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England, United Kingdom

Correspondence: Robert E. Coleman, M.D., Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield, England S10 2SJ, United Kingdom. Telephone: 44-114-226-5213; Fax: 44-114-226-5678; e-mail: r.e.coleman{at}sheffield.ac.uk

Bone is a preferred site of metastasis for many solid tumors, and the complications associated with bone metastases can result in significant skeletal morbidity including severe bone pain, pathologic fracture, spinal cord compression, and hypercalcemia of malignancy (HCM). Bisphosphonates are the current standard of care for preventing skeletal complications associated with bone metastases. Clinical trials investigating the benefit of bisphosphonate therapy have used a composite end point defined as a skeletal-related event (SRE) or bone event, which typically includes pathologic fracture, spinal cord compression, radiation or surgery to bone, and HCM. Bisphosphonates have been shown to significantly reduce the incidence of these events in patients with bone metastases. Zoledronic acid (Zometa^®; Novartis Pharmaceuticals Corp.; East Hanover, NJ), pamidronate (Aredia^®; Novartis Pharmaceuticals Corp.), clodronate (Bonefos^®; Anthra Pharmaceuticals; Princeton, NJ), and ibandronate (Bondronat^®; Hoffmann-La Roche Inc.; Nutley, NJ) all have demonstrated efficacy superior to that of placebo in patients with breast cancer. Zoledronic acid is the only bisphosphonate that has been compared directly with pamidronate, and it was shown by multiple event analysis to be significantly more effective at reducing the risk of an SRE. In patients with prostate cancer, clodronate, etidronate (Didronel^®; Procter and Gamble Pharmaceuticals, Inc.; Cincinnati, OH), and pamidronate have demonstrated transient palliation of bone pain. However, zoledronic acid is the only bisphosphonate to demonstrate both significant and sustained pain reduction and a significantly lower incidence and longer time to onset of SREs compared with placebo. Zoledronic acid is also the only bisphosphonate to demonstrate efficacy in patients with bone metastases from a variety of other solid tumors, including lung cancer and renal cell carcinoma. In conclusion, bisphosphonates effectively reduce skeletal complications in patients with bone metastases from breast cancer, and zoledronic acid has demonstrated the broadest clinical activity in patients with a wide variety of tumor types.

Key Words. Bone metastases • Phase III • Zoledronic acid • Pamidronate • Skeletal complications

This article has been cited by other articles:

				R. von Moos, C. B. Caspar, B. Thurlimann, R. Angst, R. Inauen, R. Greil, B. Bergstrom, K. Schmieding, and M. Pecherstorfer Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study Ann. Onc., July 1, 2008; 19(7): 1266 - 1270. [Abstract] [Full Text] [PDF]

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]

				K. Olson and C. Van Poznak Significance and impact of bisphosphonate-induced acute phase responses Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 223 - 229. [Abstract] [PDF]

				C. Gridelli The Use of Bisphosphonates in Elderly Cancer Patients Oncologist, January 1, 2007; 12(1): 62 - 71. [Abstract] [Full Text] [PDF]

				R. E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., October 15, 2006; 12(20): 6243s - 6249s. [Abstract] [Full Text] [PDF]

				G. Carteni, R. Bordonaro, F. Giotta, V. Lorusso, S. Scalone, V. Vinaccia, R. Rondena, and D. Amadori Efficacy and Safety of Zoledronic Acid in Patients with Breast Cancer Metastatic to Bone: A Multicenter Clinical Trial Oncologist, July 1, 2006; 11(7): 841 - 848. [Abstract] [Full Text] [PDF]

				K. Mystakidou, E. Katsouda, E. Parpa, E. Kouskouni, C. Chondros, M. L. Tsiatas, A. Galanos, and L. Vlahos A prospective randomized controlled clinical trial of zoledronic acid for bone metastases American Journal of Hospice and Palliative Medicine, January 1, 2006; 23(1): 41 - 50. [Abstract] [PDF]

				D. J. Stewart Foreword--New Directions for Topotecan in Lung Cancer Treatment Oncologist, December 1, 2004; 9(suppl_6): 1 - 3. [Full Text] [PDF]

				A. Ardizzoni Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update Oncologist, December 1, 2004; 9(suppl_6): 4 - 13. [Abstract] [Full Text] [PDF]

				P. Conte Optimizing Bisphosphonate Therapy in Oncology Oncologist, September 1, 2004; 9(suppl_4): 1 - 2. [Full Text] [PDF]

				P. Conte and V. Guarneri Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens Oncologist, September 1, 2004; 9(suppl_4): 28 - 37. [Abstract] [Full Text] [PDF]